Board summary
Key figures
55,762
Registered population
66.8% aged 18–64
8.9%
Aged 65+
ICB 14.9% · England 17.9%
66.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~25,982
Core20 residents (est.)
see page 3
5,168
Hypertension register
+5.43% in 3 yrs · England +5.60%
683
SMI register
18.4% of Salford (LAD)'s
1,081
COPD register
Reviews +16.53% in 3 yrs
Forecast to 2030
5,655
Hypertension patients, 2030
+487 on today
57.9%
QRISK ≥20% on statins, 2030
-2.59pp over 3 yrs
2.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Registered hypertension control and reviews exceed England.
Hypertension treatment to target reaches 74.7% (+13.8% three-year change vs +3.6% in England), and COPD annual reviews reach 81.7% against 76.4% nationally.
High-risk lipid therapy fell over three years.
Lipid-lowering therapy for QRISK ≥ 20% is 62.8% (-4.0% vs +6.2% in England), and statin treatment in diabetes with CVD changed by -1.6%.
Phone contact ease varies widely across practices.
Ease of phone contact spans 37.4 pp across practices, from 46.7% at Reut Medical Practice to 84.2% at Mocha Parade Medical Practice.
Population, age and ethnicity
Younger demographics contrast with 1.6% dementia prevalence across 16 catchment care homes
Across 55,762 registered patients, Broughton Health Alliance PCN is younger than benchmarks: 24.3% (13,539 patients) are aged 0-17 versus Salford (21.4%), NHS Greater Manchester ICB (21.8%), and England (19.6%). Patients aged 65+ represent 8.9% (4,977 patients) versus Salford (14.4%), the ICB (14.9%), and England (17.9%). The 0-17 share varies from 6.5% at Blackfriars to 52.0% at Reut Medical Practice. Census resident estimates record 0.4% Roma (Salford 0.2%, ICB 0.1%, England 0.2%) and 0.2% Gypsy or Irish Traveller (Salford 0.1%, ICB 0.1%, England 0.1%). Recorded learning disability prevalence is 0.4% versus Salford (0.5%) and England (0.6%).
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Salford (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Salford LA) | 2,980 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 89.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Salford LA) | 1,510 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Salford LA) | 15.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 cohort comprises 66.6% of registered patients, exceeding borough and national benchmarks
Core20 cohort (IMD quintile 1) is 66.6% across registered patients, above Salford (44.0%), NHS Greater Manchester Integrated Care Board (40.7%), and England (21.0%).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
683
SMI register
1.21% recorded prevalence
236
Learning disability register
0.42% recorded prevalence
16
Care homes, 701 beds
In the PCN catchment
9.2%
Provide unpaid care
Salford (LAD), Census 2021
The PCN records 683 severe mental illness patients (1.2% vs 1.0% England) and 16 catchment care homes with 701 beds, alongside 883 dementia patients (1.6% vs 0.8% England). Recorded learning disability prevalence is 0.4% (236 patients vs 0.6% England). Catchment beds do not establish resident occupancy.
Severe mental illness: physical health checks
Across 683 severe mental illness patients (1.2% prevalence vs 1.0% England), blood pressure checks reached 84.9% (England 83.4%) and BMI recording reached 85.6% (England 82.1%). Smoking cessation support was 92.2%, trailing Salford (94.9%) and England (94.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,168
Hypertension register
+5.43%
Register growth, 3 yrs
Salford (LAD) +5.45% · England +5.60%
+9.55pp
BP control, under 80
≤140/90 · +7.03pp aged 80+
+487
More patients by 2030
Forecast 5,655 (10.14%)
Hypertension case-finding and control
Recorded hypertension prevalence is 9.1% (5,168 patients), below Salford (12.4%), NHS Greater Manchester Integrated Care Board (14.4%) and England (15.2%), giving an unadjusted benchmark gap of +1,755 to +3,324 patients. However, 92.0% had a recent blood pressure reading (England 90.0%) and 74.7% achieved blood pressure target (England 70.3%), rising 13.8% over three years (England +3.6%). Prevalence spans from 2.2% at Blackfriars to 17.2% at Mocha Parade Medical Practice. Recorded prevalence trails regional and national benchmarks while blood pressure treatment to target exceeds England.
Lipids and statins
Lipid therapy reached 62.8% for QRISK ≥ 20% patients (England 63.6%), falling 4.0% over three years (England +6.2%). Statin uptake for diabetes with cardiovascular disease is 81.9% (England 84.4%), falling 1.6% over three years (England +1.0%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 74,090 | £1.50 | £1.94 | £1.86 | £111,135 |
| Cardiovascular (all), 2025 | 107,625 | £2.58 | £3.15 | £3.33 | £277,672 |
In 2026, the PCN prescribed 74,090 lipid-regulating drug items at £1.50 per item, below Salford (£1.54), England (£1.86) and NHS Greater Manchester Integrated Care Board (£1.94). Across these items, spend was £26,672 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+18.03%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.73%
Asthma prevalence, PCN 3-yr % change
COPD recorded prevalence is 1.9% (1,081 patients), matching England (1.9%) and below Salford (2.5%), with reviews at 81.7%, up 16.5% over three years (England +2.8%). Asthma prevalence is 4.2% (2,207 patients), below England (6.6%) and Salford (5.9%), falling 1.7% over three years (England +0.5%). While asthma reviews rose 18.0% to 71.2% (England 65.7%), an estimated 636 patients did not have a recorded review.
Cancer register and children's immunisation
Cancer recorded prevalence is 2.0% (1,108 patients), below Salford (2.9%) and England (3.8%). In Q1 2025/26, childhood immunisation coverage remains below the 95.0% target: 6-in-1 at 12 months is 72.8% (England 91.0%) and MMR dose 1 at 24 months is 67.4% (England 88.3%). At age 5, 4-in-1 pre-school booster coverage is 63.6% (England 80.9%), and MMR dose 2 (69.8%) trails MMR dose 1 (84.6%) by 14.8 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2, above England (55.3%) and up 3.1 pp from 52.4% in 2013, but 19.4 pp below the 75.0% national ambition by 2028 (about 2,270 extra early-stage cases annually across the ICB). Staging data reflects the wider ICB system, not PCN performance; stage was known for 70.8% of registrations. At PCN level, cervical screening coverage fell 4.7% over 2023 to 2025 (England -1.0%) to 51.1%, trailing England (66.8%) by 15.7 pp.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Manchester University NHS Foundation Trust achieved 80.1% on the 28-day faster diagnosis standard, meeting the 75.0% standard and exceeding England (79.3%), Northern Care Alliance NHS Foundation Trust (75.2%) and NHS Greater Manchester Integrated Care Board (79.5%), though trailing Tameside and Glossop Integrated Care NHS Foundation Trust (82.5%). However, on the 62-day referral to treatment standard, Manchester University NHS Foundation Trust reached 72.8%, remaining 12.2 pp below the 85.0% standard and trailing the ICB (75.7%), Northern Care Alliance (78.6%) and Tameside and Glossop (76.8%), although above England (71.2%).
| Pathways within standard (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 0.00 | 21.40 |
| CT | 14.66 | 4.10 | 0.18 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 0.00 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 1.51 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.45 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 0.80 | 23.14 |
| Community services activity | Salford residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 37,955 | 573,310 |
| Referrals | 3,340 | 94,470 |
| Patients with a contact | 15,440 | 183,535 |
Community services (residents of Salford), Jun 2026 (provisional). In June 2026 (provisional), adults aged 65 and over accounted for 53.9% of all community-service contacts among Salford residents (20,470 of 37,955 contacts). This activity captures local-authority resident utilization across community pathways rather than practice-registered PCN activity, highlighting substantial older-adult demand across the borough's community health services.
Practice variation and patient experience
Practice phone ease spans 37.4 pp, while good experience varies by 7.7 pp
In the 2025/26 QOF clinical domain, the England calculated comparator was 97.1%. Newbury Green Medical Practice achieved 100.0%, and Dr A Chaudhry & Dr I Jeet achieved 100.0%. In the vaccination and immunisation domain, the England calculated comparator was 55.2%. Care Homes Medical Practice achieved 15.6%, and Blackfriars achieved 52.1%. The practice range between them was 36.5 pp.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Newbury Green | 91 | 73.3 | 63.9% | 73.0% | 82.7% |
| Mocha Parade | 95 | 80.5 | 84.2% | 71.5% | 81.2% |
| Care Homes | 11 | 100.0 | — | — | 77.8% |
| Dr A Chaudhry & | 95 | 69.3 | 64.8% | 68.9% | 77.4% |
| Reut Medical | 71 | 70.5 | 46.7% | 71.6% | 76.8% |
| Blackfriars | 102 | 8.6 | 52.5% | 56.3% | 75.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eight trends lag England, led by lipid therapy and contracting learning disability registers
Across 25 compared measures, 8 three-year trends trail England. The widest relative lags are QRISK ≥ 20% lipid therapy, falling 4.0% (England +6.2%), learning disability prevalence, falling 4.1% to 0.4% (236 patients; England +5.4%), and cervical screening, falling 4.7% (England -1.0%). Sized against Salford and England benchmarks, the unadjusted learning disability register gap is +37 to +92 patients. Conversely, relative three-year strengths include breast screening (+35.0% vs England +8.4%) and COPD reviews (+16.5% vs England +2.8%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
QRISK statin treatment
Learning disability register
Cervical screening
Diabetes statin (CVD)
Asthma register
Breast screening (53-70)
COPD reviews
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Salford (LAD) | Asset | PCN | Salford (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (701 beds) | n/a | Schools (catchment) | 112 | n/a |
| Children's centres | 4 | 16 | Places of worship | 52 | 118 |
| Libraries | 1 | 16 | Primary schools (LA maintained) | 10 | 52 |
| Primary academies | 11 | 21 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Learning disability register validation audit
Recorded learning disability prevalence across the 55,762 list is 0.4% (236 patients) versus Salford (0.5%) and England (0.6%), falling 4.1% over 2023 to 2025 (Salford +1.8%, England +5.4%), an unadjusted gap of +37 to +92 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 2
Targeted opportunistic hypertension case-finding
Recorded hypertension prevalence across the 55,762 list is 9.1% (5,168 patients) versus Salford (12.4%), the ICB (14.4%) and England (15.2%), giving an unadjusted benchmark gap of +1,755 to +3,324 patients. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Practice telephony access and triage review
In the Jan-Apr 2026 GP Patient Survey, ease of phone contact spans 37.4 pp across practices, from 46.7% at Reut Medical Practice to 84.2% at Mocha Parade Medical Practice (England 56.9%), across a 66.6% Core20 PCN. Low cost, quick to run.
Evidence base: patient-reported access and experience is the demand-side signal on primary-care capacity and access model; practices with sustained poor experience are the ones to prioritise for access-model support.
Policy anchor: 10 Year Health Plan, shift from hospital to community (Neighbourhood Health Service).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register validation (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| SMI smoking cessation review (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case finding review (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall campaign (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Primary care telephony access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Learning disability register validation audit (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 2 · Targeted opportunistic hypertension case-finding (p12) | Hypertension register · Hypertension: QOF prevalence · Aged 65+ | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Practice telephony access and triage review (p12) | GPPS easy to contact the practice by phone · GPPS survey response rate · Core20 cohort (IMD quintile 1) | 10YHP, hospital to community · Core20PLUS5 · 10YHP equity test | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
